[{"id":"fb5a3d64-2b8f-44c4-84f0-e927e52ab2a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939051","created_at":"2024-02-29T18:31:43.001Z","updated_at":"2025-02-25T13:35:51.854Z","phase":"Phase 2","brief_title":"Obeticholic Acid for Prevention in Barrett's Esophagus","source_id_and_acronym":"NCT04939051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FGF19 • SOX2 • CASP3 • FGF • CDX2","pipe":"","alterations":" ","tags":["FGF19 • SOX2 • CASP3 • FGF • CDX2"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/03/2024","start_date":" 01/03/2024","primary_txt":" Primary completion: 09/29/2025","primary_completion_date":" 09/29/2025","study_txt":" Completion: 09/29/2026","study_completion_date":" 09/29/2026","last_update_posted":"2025-02-21"},{"id":"342c2212-312d-4751-97cb-897cdaabd015","acronym":"","url":"https://clinicaltrials.gov/study/NCT06817525","created_at":"2025-02-25T15:38:27.775Z","updated_at":"2025-02-25T15:38:27.775Z","phase":"Phase 2","brief_title":"Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC","source_id_and_acronym":"NCT06817525","lead_sponsor":"Henan Cancer Hospital","biomarkers":" CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • AiRuiKa (camrelizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/06/2024","start_date":" 11/06/2024","primary_txt":" Primary completion: 11/06/2025","primary_completion_date":" 11/06/2025","study_txt":" Completion: 11/06/2025","study_completion_date":" 11/06/2025","last_update_posted":"2025-02-10"},{"id":"0fa68358-5ca0-4783-89e5-388a03a0323e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02421185","created_at":"2021-01-18T11:34:41.906Z","updated_at":"2025-02-25T16:58:47.423Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT02421185","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGF","pipe":"","alterations":" ","tags":["FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 05/25/2015","start_date":" 05/25/2015","primary_txt":" Primary completion: 05/13/2019","primary_completion_date":" 05/13/2019","study_txt":" Completion: 05/16/2019","study_completion_date":" 05/16/2019","last_update_posted":"2025-02-03"},{"id":"94c5e31a-2356-49e3-9f8b-a6c9b2c0747c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02298959","created_at":"2023-12-06T16:15:23.236Z","updated_at":"2024-07-02T16:34:58.835Z","phase":"Phase 1","brief_title":"Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer","source_id_and_acronym":"NCT02298959","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • HGF • CTAG1B • CD4 • FGF • MLANA","pipe":"","alterations":" ","tags":["CD8 • HGF • CTAG1B • CD4 • FGF • MLANA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 04/08/2015","start_date":" 04/08/2015","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-05"},{"id":"ec6940fc-f4eb-4116-af93-70615de3189c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00049530","created_at":"2021-01-18T00:05:10.214Z","updated_at":"2024-07-02T16:35:44.354Z","phase":"Phase 2","brief_title":"PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma","source_id_and_acronym":"NCT00049530","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" FGF","pipe":"","alterations":" ","tags":["FGF"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 01/13/2004","start_date":" 01/13/2004","primary_txt":" Primary completion: 08/01/2012","primary_completion_date":" 08/01/2012","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2023-06-29"},{"id":"30c12ff9-e4f6-4aaa-b23a-ab2e125bc519","acronym":"","url":"https://clinicaltrials.gov/study/NCT03392584","created_at":"2021-11-18T23:54:56.929Z","updated_at":"2024-07-02T16:35:51.638Z","phase":"","brief_title":"Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters","source_id_and_acronym":"NCT03392584","lead_sponsor":"Oslo University Hospital","biomarkers":" VEGFA • IL6 • CXCL10 • IL2 • IL10 • CCL2 • FGF • IL17A","pipe":"","alterations":" ","tags":["VEGFA • IL6 • CXCL10 • IL2 • IL10 • CCL2 • FGF • IL17A"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 01/08/2022","study_completion_date":" 01/08/2022","last_update_posted":"2023-04-03"},{"id":"3a1a5254-3234-4524-b5ba-287fea6ff089","acronym":"","url":"https://clinicaltrials.gov/study/NCT03823651","created_at":"2021-03-02T16:53:11.206Z","updated_at":"2024-07-02T16:35:58.847Z","phase":"","brief_title":"A Research Program Targeting Pre- and Peri-transplant Optimization Program (R-PPOP)","source_id_and_acronym":"NCT03823651","lead_sponsor":"Duke University","biomarkers":" IL6 • FLT1 • IL2 • IL10 • VEGFC • FGF • IL17A • IL23A • IL17C • IL21 • IL22 • TSLP • VCAM1 • IL16","pipe":"","alterations":" ","tags":["IL6 • FLT1 • IL2 • IL10 • VEGFC • FGF • IL17A • IL23A • IL17C • IL21 • IL22 • TSLP • VCAM1 • IL16"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/27/2019","start_date":" 06/27/2019","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-12-20"},{"id":"20efeb70-a46d-4b47-9855-0576c986d562","acronym":"","url":"https://clinicaltrials.gov/study/NCT04374747","created_at":"2021-01-18T21:08:05.002Z","updated_at":"2024-07-02T16:36:00.953Z","phase":"","brief_title":"Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk","source_id_and_acronym":"NCT04374747","lead_sponsor":"University of Massachusetts, Amherst","biomarkers":" IL6 • TNFA • CXCL8 • FLT1 • VEGFD • FGF • IL1B • LEP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • FLT1 • VEGFD • FGF • IL1B • LEP"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/24/2019","start_date":" 10/24/2019","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2022-11-04"},{"id":"863f301c-d7ce-401c-a561-44e816aa2de5","acronym":"BOOSTER","url":"https://clinicaltrials.gov/study/NCT01989780","created_at":"2021-01-18T09:04:26.431Z","updated_at":"2024-07-02T16:36:06.061Z","phase":"Phase 2","brief_title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","source_id_and_acronym":"NCT01989780 - BOOSTER","lead_sponsor":"Japan Breast Cancer Research Group","biomarkers":" HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • fulvestrant • letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 160","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2022-08-04"},{"id":"44b23d2a-b087-4118-a03c-973d0274971d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03753399","created_at":"2021-01-18T18:27:13.189Z","updated_at":"2024-07-02T16:36:29.974Z","phase":"","brief_title":"Effect of Acupuncture for QoL in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy: a Pilot Study","source_id_and_acronym":"NCT03753399","lead_sponsor":"Guangzhou University of Traditional Chinese Medicine","biomarkers":" CD8 • IFNG • IL6 • TNFA • CXCL12 • IL2 • IL10 • CCL4 • FGF • IL18 • IL17A • IL23A • IFNA1 • IL1B • IL21 • IL22 • BDNF","pipe":"","alterations":" ","tags":["CD8 • IFNG • IL6 • TNFA • CXCL12 • IL2 • IL10 • CCL4 • FGF • IL18 • IL17A • IL23A • IFNA1 • IL1B • IL21 • IL22 • BDNF"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 04/27/2020","primary_completion_date":" 04/27/2020","study_txt":" Completion: 04/27/2020","study_completion_date":" 04/27/2020","last_update_posted":"2021-05-20"},{"id":"1e9e23ff-6f7f-4adf-b6df-acfe8db81bb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01697605","created_at":"2021-01-18T07:22:41.625Z","updated_at":"2024-07-02T16:36:37.655Z","phase":"Phase 1","brief_title":"A Phase I Study of Oral BGJ398 in Asian Patients","source_id_and_acronym":"NCT01697605","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGF","pipe":"","alterations":" ","tags":["FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 10/19/2012","start_date":" 10/19/2012","primary_txt":" Primary completion: 02/07/2019","primary_completion_date":" 02/07/2019","study_txt":" Completion: 02/07/2019","study_completion_date":" 02/07/2019","last_update_posted":"2020-12-08"},{"id":"931a0803-d4c8-4f98-9bb6-97e87c40e482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01956669","created_at":"2021-01-18T08:52:55.254Z","updated_at":"2024-07-02T16:36:42.063Z","phase":"Phase 2","brief_title":"Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors","source_id_and_acronym":"NCT01956669","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KIT • KDR • AFP • FLT1 • VEGFC • FGF","pipe":"","alterations":" ","tags":["KIT • KDR • AFP • FLT1 • VEGFC • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 10/08/2014","start_date":" 10/08/2014","primary_txt":" Primary completion: 11/05/2019","primary_completion_date":" 11/05/2019","study_txt":" Completion: 11/05/2019","study_completion_date":" 11/05/2019","last_update_posted":"2020-08-12"},{"id":"1cdd39b3-bcbf-40a7-85b9-568ba1dbfea5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01266031","created_at":"2021-01-18T05:07:02.377Z","updated_at":"2025-02-25T16:01:07.603Z","phase":"Phase 1/2","brief_title":"Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma","source_id_and_acronym":"NCT01266031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" VEGFA • CXCL12 • FGF","pipe":"","alterations":" ","tags":["VEGFA • CXCL12 • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Zolinza (vorinostat)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 07/12/2011","start_date":" 07/12/2011","primary_txt":" Primary completion: 06/30/2015","primary_completion_date":" 06/30/2015","study_txt":" Completion: 01/31/2017","study_completion_date":" 01/31/2017","last_update_posted":"2018-07-31"},{"id":"a05c3ff4-1d35-42ee-99b9-d78d41b00e4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02835833","created_at":"2021-01-18T13:55:01.923Z","updated_at":"2024-07-02T16:37:09.067Z","phase":"Phase 1","brief_title":"Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors","source_id_and_acronym":"NCT02835833","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" VEGFA • PIGF • FGF","pipe":"","alterations":" ","tags":["VEGFA • PIGF • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/09/2016","start_date":" 06/09/2016","primary_txt":" Primary completion: 04/14/2018","primary_completion_date":" 04/14/2018","study_txt":" Completion: 06/14/2018","study_completion_date":" 06/14/2018","last_update_posted":"2018-07-10"},{"id":"b90c7697-6311-4262-9536-bc47534419d3","acronym":"AMALTHEA","url":"https://clinicaltrials.gov/study/NCT02129257","created_at":"2021-01-18T09:52:23.572Z","updated_at":"2024-07-02T16:37:16.932Z","phase":"Phase 2","brief_title":"Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT02129257 - AMALTHEA","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" KDR • HGF • HIF1A • FLT1 • VEGFB • VEGFC • FGF • NRP1","pipe":"","alterations":" ","tags":["KDR • HGF • HIF1A • FLT1 • VEGFB • VEGFC • FGF • NRP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 05/26/2014","start_date":" 05/26/2014","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 09/25/2017","study_completion_date":" 09/25/2017","last_update_posted":"2017-10-24"},{"id":"6dd62ac3-f742-44c5-864f-fb16759eaf30","acronym":"","url":"https://clinicaltrials.gov/study/NCT02928575","created_at":"2021-01-18T14:23:03.367Z","updated_at":"2024-07-02T16:37:28.602Z","phase":"Phase 2","brief_title":"Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma","source_id_and_acronym":"NCT02928575","lead_sponsor":"Bassam Abdulkarim","biomarkers":" IL6 • CXCL12 • FGF","pipe":"","alterations":" ","tags":["IL6 • CXCL12 • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • temozolomide"],"overall_status":"Unknown status","enrollment":" Enrollment 45","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2016-10-10"}]